Clinical trial
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus: A 40 Week Randomized, Double Blind, Placebo Controlled, Follow-Up to Protocol 15-50310.
NCT01585558 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus: A 40 Week Randomized, Double Blind, Placebo Controlled, Follow-Up to Protocol 15-50310.
- Lead sponsor
- Shionogi
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 16, 2006
- Completion date
- September 18, 2008
- Enrollment
- 180 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.